153223-23-5 Usage
Description
(4R,5S,6S,7R)-1,3,4,7-tetrabenzyl-5,6-dihydroxy-1,3-diazepan-2-one is a complex organic molecule with a molecular formula of C36H36N2O2. It is a chiral compound belonging to the class of diazepan-2-ones, which are heterocyclic compounds featuring a seven-membered ring with one nitrogen atom and one oxygen atom. This specific compound is a derivative of diazepan-2-one, characterized by the presence of four benzyl groups attached to the nitrogen atom and two hydroxyl groups on the ring. It is synthesized for research purposes in organic chemistry and pharmaceuticals, due to its unique structural features and potential applications.
Uses
Used in Pharmaceutical Research:
(4R,5S,6S,7R)-1,3,4,7-tetrabenzyl-5,6-dihydroxy-1,3-diazepan-2-one is used as a research compound for exploring its potential pharmaceutical applications. Its unique structure and chirality make it an interesting candidate for the development of new drugs targeting various diseases and conditions.
Used in Organic Chemistry:
In the field of organic chemistry, (4R,5S,6S,7R)-1,3,4,7-tetrabenzyl-5,6-dihydroxy-1,3-diazepan-2-one serves as a key intermediate or building block in the synthesis of more complex molecules. Its functional groups and stereochemistry can be exploited to create a variety of novel compounds with diverse properties and potential applications.
Used in Drug Delivery Systems:
Similar to gallotannin, (4R,5S,6S,7R)-1,3,4,7-tetrabenzyl-5,6-dihydroxy-1,3-diazepan-2-one could potentially be used in drug delivery systems. Its structural features may allow for the development of innovative carriers or enhancers for drug molecules, improving their delivery, bioavailability, and therapeutic outcomes.
Used in Chemical Synthesis:
(4R,5S,6S,7R)-1,3,4,7-tetrabenzyl-5,6-dihydroxy-1,3-diazepan-2-one may also find use in chemical synthesis, where it could serve as a precursor to other complex organic molecules. Its unique structure and functional groups could be utilized in the creation of new materials with specific properties for various applications, such as in the fields of materials science, nanotechnology, or environmental chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 153223-23-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,3,2,2 and 3 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 153223-23:
(8*1)+(7*5)+(6*3)+(5*2)+(4*2)+(3*3)+(2*2)+(1*3)=95
95 % 10 = 5
So 153223-23-5 is a valid CAS Registry Number.
InChI:InChI=1/C33H34N2O3/c36-31-29(21-25-13-5-1-6-14-25)34(23-27-17-9-3-10-18-27)33(38)35(24-28-19-11-4-12-20-28)30(32(31)37)22-26-15-7-2-8-16-26/h1-20,29-32,36-37H,21-24H2/t29-,30-,31+,32+/m1/s1
153223-23-5Relevant articles and documents
Grignard addition to aldonitrones. Stereochemical aspects and application to the synthesis of C2-symmetric diamino alcohols and diamino diols
Dondoni, Alessandro,Perrone, Daniela,Rinaldi, Marilisa
, p. 9252 - 9264 (2007/10/03)
A new example of the stereoselective installation of the amino group at a saturated carbon center via organometallic addition of chiral aldehydes to nitrones is illustrated by the synthesis of 1,3-diamino propanol 1 and 1,4- diamino butandiol 2 units. Three diamino alcohol 1 stereotriads were obtained by stereoselective addition of alkylmagnesium halides (benzyl, cyclohexylmethyl, and metallyl) to the N-benzyl nitrones derived from β- amino-α-hydroxy aldehydes followed by reduction of the resulting N- benzylhydroxylamines. Three 1,4-dibenzyl substituted stereoisomers of type 2 with fixed S configuration at C2 and C3 were prepared by sequential and simultaneous amination in two directions starting from L-threose nitrone and L-tartraldehyde bis-nitrone, respectively. The R,S,S,R isomer obtained by the former route was converted into a seven-membered ring cyclic urea (1,3- diazapin-2-one), i.e., a compound that belongs to a class of nonpeptide HIV- 1 protease inhibitors.
Preparation and structure-activity relationship of novel P1/P1'- substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors
Nugiel,Jacobs,Worley,Patel,Kaltenbach III,Meyer,Jadhav,De Lucca,Smyser,Klabe,Bacheler,Rayner,Seitz
, p. 2156 - 2169 (2007/10/03)
A series of novel P1/P1'-substituted cyclic urea-based HIV-1 protease inhibitors was prepared. Three different synthetic schemes were used to assemble these compounds. The first approach uses amino acid-based starting materials and was originally used to prepare DMP 323. The other two approaches use L-tartaric acid or L-mannitol as the starting material. The required four contiguous R,S,S,R centers of the cyclic urea scaffold are introduced using substrate control methodology. Each approach has specific advantages based on the desired P1/P1' substituent. Designing analogs based on the enzyme's natural substrates provided compounds with reduced activity. Attempts at exploiting hydrogen bond sites in the S1/S1' pocket, suggested by molecular modeling studies, were not fruitful. Several analogs had better binding affinity compared to our initial leads. Modulating the compound's physical properties led to a 10-fold improvement in translation resulting in better overall antiviral activity.
